本帖最后由 老马 于 2013-3-13 13:43 编辑 H/ M. s! C9 P. t
d' p6 l4 n8 i, R$ C健择(吉西他滨)+顺铂+阿瓦斯汀
; Q' u- ^/ _" `9 `, A, `. \ Gemzar +Cisplatin + Avastin
, F+ K! I' R$ i0 l+ |http://annonc.oxfordjournals.org/content/21/9/1804.full
/ A3 D. a& M8 F7 [- ~Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' T. G1 E7 i3 c) nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
# S. ^8 l" A+ y* S) `Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. * R' z& m |8 K
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 841)
|0 r/ B" M3 m2 ]2 d0 y
华为网盘附件:
8 N' U) I( s. Z: p4 e【华为网盘】ava.JPG5 H+ m! U' j5 Q; l+ B" Z
|